Aim This review article summarizes the current clinical practice guidelines around disease
definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer …

Simple Summary The clinical management of bladder cancer has been developing in the
past decade, including diagnostic tools and treatment options. Both monotherapy and …

Urothelial carcinoma (UC), the sixth most common cancer in Western countries, includes
upper tract urothelial carcinoma (UTUC) and bladder carcinoma (BC) as the most common …

Abstract Purpose of Review The treatment options for high-risk non-muscle invasive bladder
cancer (NMIBC), particularly following BCG, remain limited. We highlight recent, promising …

Non-muscle invasive bladder cancer (NMIBC) has traditionally been managed with
transurethral resection followed by intravesical chemotherapy and/or bacillus Calmette …

The current landscape of salvage therapies for patients with... : Current Opinion in Urology The
current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive …

Simple Summary Bladder cancer is a common disease in urological patients. The approach
to treatment depends on the severity of the tumor; in this article, we focus on tumors that do …

Objectives We conducted the first phase I dose-escalation trial (NCT02324582) of
intravesical Bacillus Calmette–Guérin (BCG) in combination with systemic pembrolizumab in …

Bladder cancer is the 10th most frequently diagnosed cancer worldwide with 5-year survival
rate around 70%. The current first-line treatment for non-muscle invasive bladder cancer is …

Non-muscle invasive bladder cancer (NMIBC) is a common urological malignancy, and
bacillus Calmette-Guérin (BCG) therapy is the gold standard treatment in intermediate and …